Journal
BREAST CANCER RESEARCH
Volume 3, Issue 5, Pages 328-331Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/bcr316
Keywords
bioreductive drugs; hypoxia; hypoxia responsive element; reductase enzymes
Categories
Funding
- Medical Research Council [G0500366] Funding Source: Medline
Ask authors/readers for more resources
Conclusive research has shown that regions of acute/chronic hypoxia, which exist within the majority of solid tumours, have a profound influence on the therapeutic outcome of cancer chemotherapy and radiotherapy and are a strong prognostic factor of disease progression and survival. A strong argument therefore exists for assessing the hypoxic fraction of tumours, prior to patient treatment, and to tailor this treatment accordingly. Tumour hypoxia also provides a powerful physiological stimulus that can be exploited as a tumour-specific condition, allowing for the rationale design of hypoxia-activated anticancer drugs or novel hypoxia-regulated gene therapy strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available